biote (NASDAQ:BTMD - Get Free Report) posted its earnings results on Wednesday. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.01, Zacks reports. biote had a negative return on equity of 32.41% and a net margin of 5.20%.
biote Stock Performance
NASDAQ BTMD traded down $0.03 on Wednesday, hitting $4.10. 286,012 shares of the stock were exchanged, compared to its average volume of 138,624. biote has a 52-week low of $4.03 and a 52-week high of $8.44. The firm has a market capitalization of $222.78 million, a P/E ratio of 15.77 and a beta of 1.07. The stock has a fifty day moving average price of $5.11 and a two-hundred day moving average price of $5.60.
Wall Street Analyst Weigh In
Separately, Craig Hallum started coverage on shares of biote in a research report on Monday, December 16th. They set a "buy" rating and a $12.00 price objective for the company.
Read Our Latest Research Report on biote
About biote
(
Get Free Report)
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider biote, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and biote wasn't on the list.
While biote currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
